COVID-19 information BNSSG Adult Joint Formulary
17. Miscellaneous Preparations
| First line drugs | Second line drugs | Specialist drugs | Secondary care drugs |
| Recommended in both primary and secondary care | Alternatives (often in specific conditions) in both primary and secondary care | Where a specialist input is needed (see introduction for definition) | Prescribing principally within secondary care only |
Miscellaneous Preparations
This page is for medicinal products that have been through the Joint Formulary Process, and therefore are Formulary within BNSSG, however they are not listed within the BNF.
All are TLS Red
Acid citrate dextrose
- 500mL bags for use with Cell Saver machine
- UHBW only
Autologous chondrocyte implantation
- As per NICE TA477 Autologous chondrocyte implantation for treating symptomatic articular cartilage defects of the knee
- As per NICE TA508 Autologous chondrocyte implantation using chondrosphere for treating symptomatic articular cartilage defects of the knee
Bone morphogenetic protein (Inductos®, Osigraft®)
- N.B. Not for Complex spinal surgery - NHS England is the commissioner for this indication and they are not routinely commissioned. An IFR application is required
Eleview® lifting solution
- Lifting solution for endoscopic submucosal dissection (ESD) of polyps
Independence Wound Protection/Collection Pouch Covers: VAP 1 (small), VAP 2 (regular), VAP 3 (large)
- Dialysis pouch covers are not routinely recommended by renal dialysis teams, advise the patient to contact the dialysis team before purchasing covers
Lutetium (177Lu) oxodotreotide
- As per NICE TA541 for treating unresectable or metastatic neuroendocrine tumours
Lutetium (177Lu) vipivotide tetraxetan
- As per NHSE SCC 2362 for patients with prostate-specific membrane antigen (PSMA)-positive metastatic castration-resistant prostate cancer (mCRPC) who have been treated with androgen receptor (AR) pathway inhibition and taxane-based chemotherapy or who are not medically suitable for taxanes
Methoxsalen (Uvadex®)
- For use by the Bristol Therapeutic Apheresis Unit for Photopheresis
Perflutren (Luminity®)
- For ultrasound contrast-enhancing agent for use in adult patients as an alternative to SonoVue®
Regadenoson (Rapiscan®)
- For use as a pharmacological stress agent for radionuclide myocardial perfusion imaging (MPI) in adult patients unable to undergo adequate exercise stress
Sulfur hexafluoride lipid microspheres (SonoVue®)
- For use in Echocardiography, in patients with suspected or established cardiovascular disease to provide opacification of cardiac chambers and enhance left ventricular endocardial border delineation
- SonoVue® should only be used in patients where study without contrast enhancement is inconclusive
Sulfur hexafluoride lipid microspheres (SonoVue®)
- For characterising indeterminate liver lesions, assessment of vascularity or blood flow for patients where an MRI or CT scan is unsuitable
Veraseal®
- For improvement of haemostatis in urology and cardiac surgery
Poisoning
All medicines that are listed on the Royal College of Emergency Medicine and National Poisons Information Service Guideline on Antidote Availability for Emergency Departments are automatically included on the formulary as Red for use as per local Trust protocol. Please see RCEM guideline.
Contact Us
Got a question or comment about the Joint Formulary?
Please use the email address below to contact us and we will endeavour to respond within 2 working days.
BNSSG.formulary@nhs.net